Inogen Inc. (NASDAQ:INGN) shares dropped 0.9% during mid-day trading on Friday . The stock traded as low as $51.12 and last traded at $51.93, with a volume of 376,986 shares trading hands. The stock had previously closed at $52.40.

INGN has been the topic of several recent analyst reports. Zacks Investment Research lowered Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Piper Jaffray Cos. initiated coverage on Inogen in a research report on Thursday, March 24th. They set a “neutral” rating and a $46.00 target price on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $52.00 target price (up from $46.00) on shares of Inogen in a research report on Tuesday, May 10th. Needham & Company LLC reaffirmed a “strong-buy” rating and set a $58.00 target price on shares of Inogen in a research report on Thursday, June 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $60.00 target price on shares of Inogen in a research report on Wednesday, June 8th. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $52.83.

The firm’s 50-day moving average price is $48.50 and its 200 day moving average price is $42.09. The stock has a market cap of $1.03 billion and a price-to-earnings ratio of 88.13.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Monday, May 9th. The medical technology company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by $0.01. The business earned $43 million during the quarter, compared to the consensus estimate of $41.75 million. During the same period last year, the business earned $0.08 earnings per share. Inogen’s revenue was up 27.6% compared to the same quarter last year. On average, equities research analysts anticipate that Inogen Inc. will post $0.60 EPS for the current fiscal year.

In other Inogen news, EVP Brenton Taylor sold 6,500 shares of Inogen stock in a transaction dated Wednesday, April 13th. The stock was sold at an average price of $48.00, for a total transaction of $312,000.00. Following the completion of the sale, the executive vice president now directly owns 31,851 shares of the company’s stock, valued at approximately $1,528,848. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Raymond Huggenberger sold 20,747 shares of Inogen stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $47.86, for a total value of $992,951.42. Following the sale, the chief executive officer now directly owns 27,555 shares of the company’s stock, valued at $1,318,782.30. The disclosure for this sale can be found here.

A number of hedge funds have made changes to their positions in the company. California State Teachers Retirement System increased its stake in shares of Inogen by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,132 shares of the medical technology company’s stock worth $1,168,000 after buying an additional 400 shares during the period. Sei Investments Co. increased its stake in Inogen by 18.1% in the fourth quarter. Sei Investments Co. now owns 31,851 shares of the medical technology company’s stock valued at $1,277,000 after buying an additional 4,880 shares during the last quarter. First Trust Advisors LP purchased a new stake in Inogen during the fourth quarter valued at $2,419,000. Kornitzer Capital Management Inc. KS increased its stake in Inogen by 87.3% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 256,370 shares of the medical technology company’s stock valued at $10,278,000 after buying an additional 119,470 shares during the last quarter. Finally, Pembroke Management LTD purchased a new stake in Inogen during the fourth quarter valued at $10,118,000.

Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems, such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.